Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $6.00 by Analysts at Wells Fargo & Company

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective reduced by Wells Fargo & Company from $8.00 to $6.00 in a research note released on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

A number of other analysts have also issued reports on ZNTL. HC Wainwright cut their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group reduced their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday. Guggenheim decreased their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Down 12.2 %

NASDAQ:ZNTL opened at $1.66 on Thursday. Zentalis Pharmaceuticals has a fifty-two week low of $1.66 and a fifty-two week high of $18.07. The company has a 50 day moving average price of $2.97 and a 200 day moving average price of $3.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Aigen Investment Management LP purchased a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Capstone Investment Advisors LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $48,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after buying an additional 5,333 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.